Barclays raised the firm’s price target on Universal Health (UHS) to $268 from $262 and keeps an Overweight rating on the shares post the Q4 report. The company posted a modest miss as acute volumes decelerated, but still guided 2026 EBITDA ahead of Street estimates, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UHS: